INTRODUCTION

Bronchiectasis is a chronic and disabling lung disease marked by bronchial wall permanent and abnormal expansions. This condition results in compromised function of mucociliary clearance mechanisms, leading to a persistent cough, copious mucus production, and frequent respiratory infections. In addition to making breathing difficult, bronchiectasis can cause fatigue, chest pain and significantly reduce patients’ quality of life.^1-2It can be caused by various etiologies, such as autoimmune diseases (rheumatoid arthritis and Sjögren’s syndrome), severe infections (tuberculosis and bacterial pneumonia), genetic abnormalities (cystic fibrosis and primary ciliary dyskinesia) and acquired diseases.³

The use of antibiotics is an important part of the treatment for non-fibrocystic bronchiectasis.³ Several classes of antibiotics and formulations tested have already established their role in providing clinical benefits, especially in patients with an exacerbator profile.³ An exacerbator profile is defined as a worsening of respiratory symptoms treated with oral or intravenous antibiotics.⁴ Macrolides are widely used antibiotics in the treatment of bronchiectasis due to their ease of administration, anti-inflammatory properties, and efficacy in cystic fibrosis and other neutrophilic diseases.⁴ Moreover, macrolides have the advantages of high plasma concentration, long half-life, and broad antimicrobial spectrum.⁴ All of this provides justification for this class of antibiotics to be used as maintenance therapy in patients with non-fibrocystic bronchiectasis and for prevention of exacerbations.⁵ Macrolides inhibit protein production by reversibly binding to the 50S ribosomal subunit of susceptible microorganisms, blocking mRNA translation without interfering with nucleic acid synthesis. However, the widespread use of these antibiotics has inevitably led to the spread of resistant strains.⁶ The two most common mechanisms of resistance are excretion of the drug from the cell and modification of the drug target site. Resistance can occur in long-term treatment prescriptions, especially in chronic diseases such as cystic fibrosis and bronchiectasis, where frequent and continuous use of macrolides can select resistant strains.⁴ Developing more details about these mechanisms and the clinical conditions under which resistance is most likely helps to elucidate the complexity of the problem and the need for appropriate management strategies to prevent antimicrobial resistance. ^4,6

Currently, antimicrobial resistance is considered a global threat to health and development according to the World Health Organization (WHO).⁸ Accordingly, it is known that this phenomenon leads to increased costs and overload of health systems, since patients infected with resistant pathogens are hospitalized for longer and use more expensive drugs.^9-10 Recently, due to the COVID-19 pandemic, many antibiotics have been prescribed, without taking into account the potential for increased antimicrobial resistance, which generates a global scenario of uncertainty regarding the future effectiveness of the antibiotics that exist today.⁸ Therefore, this article aimed to assess the impact of antibiotic therapy with macrolides in non-fibrocystic bronchiectasis on the emergence of bacterial resistance through a systematic review.

METHODS

Experimental design and selection criteria

This is a descriptive systematic review that adopted the Preferred Items of Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Therefore, the following items were considered: eligibility criteria; exclusion criteria; information source and search strategy;selection of studies; and data collection.

Eligibility and exclusion criteria

In this study, were defined as eligibility criteria: i) experimental articles dealing with non-cystic fibrous bronchiectasis, regardless of the age group; ii) articles showing results regarding antimicrobial resistance to macrolides; iii) articles available in Portuguese, English and/or Spanish published until August 2020 in the PubMed, LILACS and SciELO databases. Reviews, editorials and personal views as well as articles not available in full and/or that did not address macrolide resistance involving patients with non-cystic fibrosis bronchiectasis were excluded.

Article search and selection strategies

Study selection, data collection, risk of bias in individual studies were carried out during the period from July to August 2020. Through the keywords “antimicrobial resistance” and “bronchiectasis”, using the Boolean operator “AND”. So, 295 articles were found; among these, 47 were selected for full reading (by two researchers, independently, reducing the risk of bias) based on the title. However, 42 articles were discarded due to eligibility criteria, resulting in five articles for analysis (Figure 1).

RESULTS AND DISCUSSION

Among the five selected studies, four were placebo-controlled clinical studies and a prospective cohort study.^9–13 Three studies assessed the effects of macrolides in children.^11–13 All clinical trials, in turn, were conducted between 2008 and 2016 involving the population of Australia, New Zealand and the Netherlands. Important information about these studies is shown in the following table (Table 1).

Only one study assessed the emergence of erythromycin-resistant commensal Streptococcus in an oropharyngeal sample (p<0.001). All others focused on azithromycin as the macrolide of choice, demonstrating a significant relationship between different administration protocols of this antimicrobial and the increase in resistant microorganisms in sputum and nasopharynx samples. Thus, through an oropharyngeal smear for Streptococcus culture and macrolide sensitivity test, it was possible to show that the use of erythromycin significantly increased the proportion of Streptococcus resistant to macrolides (27.7% vs 0.04% or placebo; p < 0.001).²²

Despite the increase in resistant pathogens, the use of erythromycin reduced the number of exacerbations (76 exacerbations per year for the erythromycin group vs 114 for the placebo group; p = 0.003).¹¹ This study emphasized the need to assess both the advantages and disadvantages of using this treatment. Although it may improve quality of life by reducing exacerbations, on the other hand, it may induce the emergence of resistant bacteria.¹¹ The resistance hypothesis suggests that while erythromycin has clinical benefits, continuous use may lead to the selection of resistant microorganisms. Bacteria exposed to antibiotics on a sublethal level may develop resistance mechanisms such as altering the antibiotic’s target, activating the drug’s enzyme, or altering the flow channels. While erythromicin may alleviate symptoms and improve patients’ quality of life, indiscriminate use may contribute to a larger public health issue: the spread of drug-resistant pathogens.

On the other hand, in 2013, Altenburg et al. found comparable resistance patterns between groups (35% macrolide resistance among patients in the azithromycin group vs 27.5% in patients in the placebo group). However, during treatment, among patients receiving azithromycin, 88% of microorganisms became resistant to macrolides, compared to 26% in the placebo group (p = 0.001). Among the most frequently isolated microorganisms, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, Moraxella catarrhalis and Haemophilus parainfluenzae stand out, which together comprised 87% of the total number of pathogens, 75% of which were tested for resistance to macrolides.¹¹In addition to the bronchiectasis, this class of antimicrobial agents has also been recommended as the first line for the treatment of community-acquired pneumonia, which may impact the emergence of resistant microorganisms (commensals or pathogens) not only in exacerbation episodes in patients with non-cystic fibrosis bronchiectasis, but also in other infectious episodes that affect this group of patients. Therefore, it is indicated that the use of macrolides as maintenance therapy occurs only in those patients who have three or more annual exacerbations.

Regarding the action of azithromycin in reducing pulmonary exacerbations, a multicenter, double-blind, randomized controlled trial conducted in Australia demonstrated that the group that received azithromycin was less prone to pulmonary exacerbations.¹³ However, the chances of boosting bacterial resistance to azithromycin were seven times greater in the azithromycin-treated group than in the control group.

Valery et al. raised concerns about the long-term use of azithromycin in indigenous children with bronchiectasis unrelated to cystic fibrosis or chronic pulmonary. The prolonged use of azithromycin for patients with chronic lung diseases should be carefully considered, because, despite its advantages of improving lung function and decreasing disease exacerbations, it may lead to negative outcomes, associated with adverse effects such as hearing impairment, and the emergence of bacterial resistance in isolates from treated patients, which, in addition to decreasing bacterial colonization (of pathogenic microorganisms or microbiota), may impact the restriction of antibiotic use in future infectious processes. The study found that the possibility of bacterial resistance to azithromycin compromises treatment efficacy and can lead to more difficult-to-treat infections. Continuous use of azithromycin leads to the selection of resistant bacteria, which is exacerbated by mechanisms such as ribosome modification. As a result, it is critical to balance its use with microbiological surveillance and alternative strategies, such as antibacterial rotation cycles and antimicrobial management programs. At the same time, only two of the 12 children participating in the study who were identified as colonized with azithromycin-resistant S. pneumoniae at the last study visit already had colonization with this resistant microorganism at the beginning of the study (both in the azithromycin group), allowing to hypothesize that the continuous use of this macrolide (azithromycin - 30 mg/kg once a week for up to 24 months) may have been the booster of the resistance that emerged in these isolates at the end of the assessments.¹³

Considering the potential of antimicrobial agents in reducing exacerbations and their possible intervention in the emergence of resistant pathogens, a clinical trial carried out between 2012 and 2016, in three Australian hospitals and one New Zealand hospital, compared the daily oral use for 21 days of azithromycin and amoxicillin-clavulanate. All exacerbations resolved by day 21 of treatment in 77.3% of children receiving amoxicillin-clavulanate and 76.8% of those receiving azithromycin. Furthermore, the median time to resolution of exacerbations was four days shorter in the amoxicillin-clavulanate group than in the azithromycin group. Thus, it is evident that the macrolide does not play a fundamental and irreplaceable role in reducing the number and duration of exacerbations.¹⁴

Also, considering the exposure of colonizers to antimicrobial agents, the authors highlighted the identification of 74 pathogens in the nasal swabs of individuals recruited for the study, namely H. influenzae, S. pneumoniae, M. catarrhalis and Staphylococcus aureus. The bacteriological profile of nasal swabs, including carriage of azithromycin-resistant organisms, was similar in both treatment groups at the onset of an exacerbation. Of the children whose swabs still contained pathogens on day 21, 4/14 (29%) in the amoxicillin-clavulanate group and 8/10 (80%) who received azithromycin carried azithromycin-resistant organisms. Even though the profile of azithromycin-resistant S. aureus isolates in both treatment groups did not change over the study period, bacterial resistance was more common in the group that used azithromycin.¹⁴

The authors propose that macrolides have been used to treat other community-acquired infectious processes, which would support the presence of resistant respiratory bacterial pathogens at the beginning of the study. ¹⁴ Specifically regarding azithromycin-resistant S. aureus, it should also be highlighted that these microorganisms remain resistant even after antibiotic therapy is discontinued. In addition to this, studies indicate the presence of resistant S. aureus in local and invasive infections among indigenous children as a whole.

In a prospective cohort study, it was reported that many physicians in Australia routinely prescribe azithromycin (often long-term) to children with bronchiectasis, while in Alaska this practice is uncommon, because macrolide resistance was significantly higher in Australian children compared to those from Alaska.¹⁵ They hypothesized that the two populations would differ in their nasopharyngeal transport of potential respiratory bacterial pathogens and antibiotic resistance genes in these microorganisms. They suspect that because of variations in how antibiotics are prescribed (e.g., frequency, duration, and choice of antibiotic), the two populations may have significant differences in both colonization by respiratory pathogens and the prevalence of resistant bacterial strains. ¹⁵

About a quarter of the children involved in the study had respiratory exacerbations, and both those in Alaska and Australia had Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus colonizing their nasopharynx. On the other hand, unlike the results found in relation to colonization by S. pneumoniae which remained stable over time, Alaska and Australia differed in terms of persistence with decline among carriers of M. catarrhalis in Alaska children and H. influenzae in Australian children.¹⁵The authors are comparing the differences in the persistence of colonization by different respiratory pathogens among children in Alaska and Australia across time. The researchers found that whereas S. pneumoniae (a common respiratory pathogen) remained stable in both populations, there were notable differences in the persistence of other pathogens. In Alaska, M. catarrhalis colonization decreased over time, while in Australia, H. influenzae colonization decreased among children. This difference may reflect differences in environmental, genetic, immune, or health practices between the two populations, affecting these pathogens’ ability to remain in the respiratory tract over time.¹⁵

Therefore, in order to investigate the cumulative effect of repeated and prolonged exposure to long-term azithromycin on bacterial transport and resistance, Australian children were divided into three groups based on the frequency of azithromycin use during the study period (no use, use for up to half of the assessment time, use for more than 50% of study visits). ¹⁵ Thus, none of the assessed microorganisms showed resistance to beta-lactams, but resistance to macrolides in carriers of S. pneumoniae and S. aureus was significantly higher in Australian children compared to those from Alaska. This suggests that antibiotic prescribing practices, health policies, or other regional factors may have contributed to a greater selective pressure that favors the development of macrolide resistance in Australian children. All H. influenzae isolates from Alaskan children and 80% of Australian children were susceptible to macrolides, with resistance to isolates of S. pneumoniae, H. influenzae, and S. aureus tending to be higher in the group that used azithromycin frequently. However, S. pneumoniae resistance increased throughout the study, regardless of the type of exposure to azithromycin.¹⁵ As a result, the authors suggest that bacterial resistance is being influenced by both antibacterial use and other epidemiological dynamics.

Thus, all studies report a significant increase in resistant microorganisms compared to the placebo group when at least one macrolide was administered (the ones used in these studies being azithromycin and erythromycin), mainly related to gram-positive pathogens, as in the case of Staphylococcus aureus and Streptococcus pneumoniae. ^11,15

This scenario has often been reported for the control of exacerbations in other diseases, such as what has been pointed out since the onset of COVID-19, in which the use of azithromycin and ceftriaxone was reported in over 68% of individuals.¹⁴ In addition, the lack of clear evidence for the beneficial effects of macrolide use both in the pandemic and in bronchiectasis has already been frequently documented by health teams. ^17-18

The increase in macrolide-resistant S. pneumoniae was present in two studies ^13,15, further highlighting the possible unexpected and undesirable effects of using these antimicrobial agents, including the fact that they are often recommended as first-line agents for the treatment of community-acquired pneumonia (CAP). Thus, macrolide resistance may be a potential cause of treatment failure in patients with CAP.^13,15 Resistance to macrolides in CAP, as described in the articles, occurred due to frequent and inadequate use of these antibiotics, which promoted the selection of resistant bacteria. This resistance compromises treatment efficacy and increases the risk of therapeutic failure and clinical complications.

Azithromycin is the most prescribed macrolide in clinical practice, and its longer half-life favors the dosage (3 times a week).¹⁹ According to the Brazilian consensus on non-cystic fibrosis bronchiectasis, the use of azithromycin is indicated through continued therapy of 6-12 months for patients with bronchiectasis and at least two exacerbations per year, or those with a history of severe exacerbation, primary or secondary immunodeficiency, excluding patients with active infection by non-tuberculous mycobacteria.³

On the other hand, these therapeutic practices provide long periods of subinhibitory concentrations that increase the risk of developing antimicrobial resistance by modulating the expression of virulence and pathogenicity genes as well as efflux pumps, especially in gram positives. Moreover, the emergence of resistant strains increases the risk of its transmission to other individuals in the community.^13,19-22

Therefore, the clinical benefits need to be balanced against the risk of antimicrobial resistance, since the macrolide will not always be the best option as a rescue antimicrobial in exacerbation crises, and the increase in microbial resistance will lead to greater morbidity and mortality of the community as a whole, especially in risk groups, such as children and adults, who have been the main individuals referred in studies of bronchiectasis.^5,14

Even with the worrying situation of the emergence of microbial resistance, which according to government agencies will be the next global epidemic, there have been few studies involving this topic, especially in patients with bronchiectasis, where the infection still appears to be only yet another event in the vicious cycle of the disease. Therefore, one of the main limitations found in this review was, in addition to the lack of studies, the lack of articles highlighting the resistance associated with the prophylactic or therapeutic use of macrolides in recent years. Therefore, the urgent need to assess patients’ clinical conditions and their prognostic outcomes beyond the underlying chronic disease is evident.

The medical community needs to develop an approach to the treatment of non-fibrocystic bronchiectasis that takes into account not only the immediate benefits to individuals, but also the risks to the wider community, and prognostic outcomes that do not involve recurrent infections with impossibility of cure.²²

CONCLUSION

Bronchiectasis causes bronchial wall dilation and mucociliary dysfunction, leading to recurrent infections, cough, and sputum. Macrolides are effective antibiotics in the treatment of non-fibrocystic bronchiectasis, but their frequent use can lead to antimicrobial resistance. Studies conducted in Australia, New Zealand and the Netherlands between 2008 and 2016 found that macrolides, particularly azithromycin, can increase the emergence of resistant microorganisms. Therefore, careful monitoring is required when using macrolides to treat non-cystic fibrous bronchiectasis.

REFERENCES

1. Laska IF, Crichton ML, Shoemark A, et al. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir Med. 2019;7(10). https://doi.org/10.1016/S2213-2600(19)30185-7

2. Martins KB, Olmedo DWV, Paz MM, et al. Staphylococcus aureus and its Effects on the Prognosis of Bronchiectasis. Microb Drug Resist. 2021;27(6):823–34. https://doi.org/10.1089/mdr.2020.0352

3. Pereira MC, Athanazio RA, Dalcin PTR, et al. Consenso brasileiro sobre bronquiectasias não fibrocísticas. J Bras Pneumol. 2019;45(4):e20190122. http://doi.rg/10.1590/1806-3713/e20190122

4. Yates B, Ahmad T, Doherty M, Watson G. Bronchiectasis. Am J Respir Crit Care Med. 2015;192(7):859-860. https://doi.org/10.1164/rccm.201507-1449LE

5. Kelly C, Chalmers JD, Crossingham I, Relph N, Felix LM, Evans DJ, Milan SJ, Spencer S, Cochrane Airways Group. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018; (3). https://doi.org/10.1002/14651858.CD012406.pub2

6. Gaynor M, Mankin AS. Macrolide Antibiotics: Binding Site, Mechanism of Action, Resistance. Curr. Top. Med. Chem. 2003; 3 (9), 949-961. https://doi.org/10.2174/1568026033452159

7. Wang D, Fu W, Dai J. Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis. Med (United States). 2019;98(17): e15285. http://doi.org/10.1097/MD.0000000000015285

8. Ghosh S, Bornman C, Zafer MM. Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand? J. Infec. Public Health. 2021; 14(5):555-560. https://doi.org/10.1016/j.jiph.2021.02.011

9. Ferri M, Ranucci E, Romagnoli P, et al. Antimicrobial resistance: A global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57(13):2857-2876. http://doi.org/10.1080/10408398.2015.1077192

10. Inchingolo R, Pierandrei C, Montemurro G, et al. Antimicrobial resistance in common respiratory pathogens of chronic bronchiectasis patients: A literature review. Antibiotics. 2021;10(3):326. http://doi.org/10.3390/antibiotics10030326

11. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial. JAMA. 2013;309(12):1260-1267. http://doi.org/10.1001/jama.2013.2290

12. Altenburg J, De-Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. JAMA. 2013;309(12):1251-1259. http://doi.org/10.1001/jama.2013.1937

13. Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): A multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(8):610-620. http://doi.org/10.1016/S2213-2600(13)70185-1

14. Goyal V, Grimwood K, Byrnes CA, et al. Amoxicillin–clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet. 2018;392(10154):1197-1206. http://doi.org/10.1016/S0140-6736(18)31723-9

15. Hare KM, Singleton RJ, Grimwood K, et al. Longitudinal Nasopharyngeal Carriage and Antibiotic Resistance of Respiratory Bacteria in Indigenous Australian and Alaska Native Children with Bronchiectasis. PLoS One. 2013;8(8). https://doi.org/10.1371/journal.pone.0070478

16. Flores Z, Matienzo S. Medicación prehospitalaria en pacientes hospitalizados por COVID-19 en un hospital público de Lima-Perú. Acta Med Peru 2020; 37(3):393–395. http://dx.doi.org/10.35663/amp.2020.373.1277

17. Sultana J, Cutroneo PM, Crisafulli S, et al. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. Drug Saf [Internet]. 2020;43(8):691–8. https://doi.org/10.1007/s40264-020-00976-7

18. Freires MS, Rodrigues Junior OM. Resistência bacteriana pelo uso indiscriminado da azitromicina frente a Covid-19: uma revisão integrativa. Res Soc Dev. 2022;11(1). https://doi.org/10.33448/rsd-v11i1.25035

19. Athanazio R, Rached S. O uso de macrolídeos para bronquiectasias, Pneumologia Paulista 2016; 29 (1). http://itarget.com.br/newclients/revista-sppt/wp-content/uploads/2016/02/PP01032016.pdf

20. World Health Organization. (WHO). WHO report on surveillance of antiotic consumption. https://www.who.int/publications/i/item/who-report-on-surveillance-of-antibiotic-consumption

21. Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399 (10325):629-655. https://doi.org/10.1016/S0140-6736(21)02724-0

22. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Vol. 1, The Lancet Respir. Med. 2013. https://doi.org/10.1016/S2213-2600(13)70038-9

Información adicional

redalyc-journal-id: 5704

IR